REGN PE Ratio & Valuation,Is REGN Overvalued

REGN Relative Valuation

REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, REGN is overvalued; if below, it's undervalued.

Historical Valuation

Regeneron Pharmaceuticals Inc (REGN) is now in the Fair zone, suggesting that its current forward PE ratio of 17.21 is considered Fairly compared with the five-year average of 16.15. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 671.78 to 967.88 according to relative valuation methord.

Relative Value

Fair Zone

671.78-967.88

Current Price：812.27

Fair

17.21

10.56

EV/EBITDA

Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBITDA of 10.56. The 5-year average EV/EBITDA is 11.09. The thresholds are as follows: Strongly Undervalued below 4.98, Undervalued between 4.98 and 8.04, Fairly Valued between 14.15 and 8.04, Overvalued between 14.15 and 17.20, and Strongly Overvalued above 17.20. The current Forward EV/EBITDA of 10.56 falls within the Historic Trend Line -Fairly Valued range.

12.96

EV/EBIT

Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBIT of 12.96. The 5-year average EV/EBIT is 12.15. The thresholds are as follows: Strongly Undervalued below 5.89, Undervalued between 5.89 and 9.02, Fairly Valued between 15.27 and 9.02, Overvalued between 15.27 and 18.40, and Strongly Overvalued above 18.40. The current Forward EV/EBIT of 12.96 falls within the Historic Trend Line -Fairly Valued range.

5.37

Regeneron Pharmaceuticals Inc. (REGN) has a current PS of 5.37. The 5-year average PS is 5.69. The thresholds are as follows: Strongly Undervalued below 3.24, Undervalued between 3.24 and 4.46, Fairly Valued between 6.91 and 4.46, Overvalued between 6.91 and 8.13, and Strongly Overvalued above 8.13. The current Forward PS of 5.37 falls within the Historic Trend Line -Fairly Valued range.

14.91

P/OCF

Regeneron Pharmaceuticals Inc. (REGN) has a current P/OCF of 14.91. The 5-year average P/OCF is 15.46. The thresholds are as follows: Strongly Undervalued below 5.83, Undervalued between 5.83 and 10.65, Fairly Valued between 20.27 and 10.65, Overvalued between 20.27 and 25.09, and Strongly Overvalued above 25.09. The current Forward P/OCF of 14.91 falls within the Historic Trend Line -Fairly Valued range.

17.33

P/FCF

Regeneron Pharmaceuticals Inc. (REGN) has a current P/FCF of 17.33. The 5-year average P/FCF is 16.56. The thresholds are as follows: Strongly Undervalued below 2.75, Undervalued between 2.75 and 9.65, Fairly Valued between 23.46 and 9.65, Overvalued between 23.46 and 30.37, and Strongly Overvalued above 30.37. The current Forward P/FCF of 17.33 falls within the Historic Trend Line -Fairly Valued range.

Regeneron Pharmaceuticals Inc (REGN) has a current Price-to-Book (P/B) ratio of 2.58. Compared to its 3-year average P/B ratio of 3.18 , the current P/B ratio is approximately -18.86% higher. Relative to its 5-year average P/B ratio of 3.45, the current P/B ratio is about -25.37% higher. Regeneron Pharmaceuticals Inc (REGN) has a Forward Free Cash Flow (FCF) yield of approximately 5.30%. Compared to its 3-year average FCF yield of 4.75%, the current FCF yield is approximately 11.49% lower. Relative to its 5-year average FCF yield of 5.79% , the current FCF yield is about -8.38% lower.

2.58

P/B

Median3y

3.18

Median5y

3.45

5.30

FCF Yield

Median3y

4.75

Median5y

5.79

Competitors Valuation Multiple

The average P/S ratio for REGN's competitors is 4.63, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN) exhibits a P/S ratio of 5.37, which is 15.84% above the industry average. Given its robust revenue growth of 0.90%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of REGN increased by 20.70% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 36.03 to 40.07.

The secondary factor is the P/E Change, contributed 8.59%to the performance.

Overall, the performance of REGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

0.90%

3.72B → 3.75B

Revenue Growth

11.21%

36.03 → 40.07

Margin Expansion

8.59%

17.19 → 18.66

P/E Change

20.70%

672.98 → 812.27

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Regeneron Pharmaceuticals Inc (REGN) currently overvalued or undervalued?

What is Regeneron Pharmaceuticals Inc (REGN) fair value?

REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 671.78 to 967.88 according to relative valuation methord.

How does REGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Regeneron Pharmaceuticals Inc (REGN) as of Jan 08 2026?

As of Jan 08 2026, Regeneron Pharmaceuticals Inc (REGN) has a P/B ratio of 2.58. This indicates that the market values REGN at 2.58 times its book value.

What is the current FCF Yield for Regeneron Pharmaceuticals Inc (REGN) as of Jan 08 2026?

As of Jan 08 2026, Regeneron Pharmaceuticals Inc (REGN) has a FCF Yield of 5.30%. This means that for every dollar of Regeneron Pharmaceuticals Inc’s market capitalization, the company generates 5.30 cents in free cash flow.

What is the current Forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN) as of Jan 08 2026?

As of Jan 08 2026, Regeneron Pharmaceuticals Inc (REGN) has a Forward P/E ratio of 17.21. This means the market is willing to pay $17.21 for every dollar of Regeneron Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Regeneron Pharmaceuticals Inc (REGN) as of Jan 08 2026?

As of Jan 08 2026, Regeneron Pharmaceuticals Inc (REGN) has a Forward P/S ratio of 5.37. This means the market is valuing REGN at $5.37 for every dollar of expected revenue over the next 12 months.

REGN Valuation